Introduction
============

Depressed mood is one of the most common psychiatric problems associated with Parkinson's disease (PD), affecting up to 50% of PD patients [@b1],[@b2]. Even in patients with early disease, the presence of depressed mood has been found to be a significant predictor of more impairment in activities of daily living (ADLs) and increased need for symptomatic therapy of PD [@b3]. Although there have been positive studies [@b4], treatment with classic antidepressants has not been found to be consistently effective versus placebo in clinical trials [@b5],[@b6]. It is thought that depression in PD arises from a complex interaction of psychological and neuropathological factors. There is some evidence that the type of depression in PD is distinct from non-parkinsonian depression. The prevalence of depression is higher in PD patients than in other similarly disabled patients [@b7], and it has been suggested that PD patients have comparatively higher rates of anxiety and pessimism, and less guilt and self-reproach [@b8],[@b9]. Clinically, depressed mood may fluctuate with motor function, improving during the 'on' state and worsening during the 'off' state [@b10].

Increasing evidence from epidemiological studies indicates that depression also affects cognition and is a risk factor for dementia. Cognitive impairment is also common in PD and includes impairments in attention encoding memory and visuospatial and executive dysfunctions [@b11], the latter being mainly attributed to the disruption of the fronto-striatal circuitry.

The clinical efficacy of rasagiline is well established [@b12]. In the ADAGIO study, treatment with rasagiline was reported to improve mood symptoms on the non-motor experiences of daily living [@b13],[@b14]. In addition, results from a small randomized, double-blind, placebo-controlled study have also suggested that rasagiline may exert beneficial effects on attention and executive abilities in non-demented PD patients with cognitive impairment [@b15]. The aims of this randomized controlled study were to evaluate the potential beneficial effect of rasagiline 1 mg/day on depressive symptoms and to explore the relationship of depressive symptoms with cognitive function in idiopathic PD patients without dementia.

Methods
=======

Study setting and trial registration
------------------------------------

This was a 12-week, randomized, double-blind, placebo-controlled trial of rasagiline 1 mg/day in PD patients with depression. The study was conducted from 5 March 2010 to 2 July 2012 at 12 university hospitals or Parkinson centres in Italy. It was conducted in accordance with Good Clinical Practice guidelines and was approved by appropriate institutional review boards; all patients provided written informed consent to participate. The study is registered with the European Clinical Trials Database (EUDRA-CT number: 2009-011144-19).

Study population
----------------

Key inclusion criteria were diagnosis of PD (at least two of three cardinal signs -- resting tremor, bradykinesia, rigidity -- and no other known or suspected cause of parkinsonism), age ≥40 and \<80 years, and Hoehn−Yahr stage ≥1 and ≤3 (on treatment). Eligible patients had a Beck Depression Inventory (version BDI-IA) score ≥15 and should have been under stable (4 weeks prior to baseline) dopaminergic treatment. All stable doses of dopamine receptor agonists, levodopa/carbidopa, levodopa/benserazide and catechol-*O*-methyl transferase (COMT) inhibitors were permitted.

This study was specifically designed to be conducted in PD patients with a stable motor component, and thus patients with motor fluctuations (the presence of which may be associated with mood) were excluded from the study. Other key exclusion criteria included previous deep brain stimulation surgery; Mini-Mental State Examination \<26; a diagnosis of current or a history of major depressive episode according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria within 1 year before recruitment into the study; and presence of psychotic symptoms, e.g. hallucination and delirium. Treatment with antidepressants, antipsychotics, cholinesterase inhibitors, memantine, amantadine, anticholinergics, and the hypnotics zaleplon, zolpidem, zopiclone and antihistamines were not allowed and must have been discontinued at least 4 weeks prior to study initiation. Patients currently or previously treated with selegiline (\<90 days prior to randomization) were also excluded.

Study design
------------

Patients underwent screening and baseline assessments at visits 1 and 2 and those who met eligibility criteria were randomized 1:1 to the addition of rasagiline 1 mg/day or matching placebo according to a computer-generated randomization list. Site personnel, patients and sponsor were blinded to treatment assignment. Subsequent study visits were undertaken at weeks 4 (visit 3) and 12 (visit 4; study end). In addition, there was a safety follow-up visit at week 14.

Outcome measures
----------------

Evaluations of depressive symptoms (BDI-IA) were performed at baseline, week 4 and week 12 (study completion). Cognitive functions (cognitive test battery) and Apathy Scale (AS) were assessed at baseline and week 12. The cognitive test battery included the noun and verb naming tasks of the Aphasia Neuropsychological Examination (Esame Neuropsicologico per l'Afasia in Italian); Trail Making Test, parts A and B; Cognitive Performance Test for letters and categories; Color Naming, Word Reading and Interference Task of the Stroop Test; Clock Drawing Test; immediate and delayed recall of the Rey Auditory Verbal Learning Test; Benton Judgment of Line Orientation Test; and the copy task of the Rey--Osterrieth Complex Figure test. The Parkinson's disease quality of life questionnaire (PDQ-39) and Unified Parkinson's Disease Rating Scale (UPDRS) Parts I−IV were assessed at baseline and week 12, with additional assessments of UPDRS Parts II (ADL) and III (Motor) at week 4. All assessments were performed in the morning, preferably 2 h after the intake of the morning dose of study medication. All evaluations, with the exception of motor function (assessed by neurologists), were performed by a psychologist, neuropsychologist or physician with adequate experience.

Treatment-emergent adverse events (TEAEs) were recorded throughout the study.

Statistical analyses
--------------------

The primary efficacy variable was the change from baseline to week 12 in depressive symptoms measured by the BDI-IA total score. The primary efficacy analysis was performed on the full-analysis set (FAS) (defined as all randomized patients who took at least one dose of study medication and who had at least one valid post-baseline assessment of the primary efficacy variable). For the primary efficacy end-point, and whenever applicable for the secondary efficacy end-points, the 'last observation carried forward' technique was used to handle missing data. Comparisons between the two groups were subjected to an analysis of covariance ([ancova]{.smallcaps}) method, fitting the baseline value of BDI-IA as covariate and treatment as a fixed factor. Baseline and safety outcomes were assessed using the safety population, which included all patients who took at least one dose of study drug.

Secondary efficacy outcomes were analysed in the same way as the primary outcome variable and included change from baseline to week 12 in cognitive function as assessed by the neuropsychological battery; PDQ-39 scores; AS scores; and UPDRS Parts II and III subscores.

*Post hoc* analyses were made for the change from baseline to week 12 in UPDRS Part I (mental) items and PDQ-39 domain scores (eight domains).

Determination of sample size
----------------------------

Based on experience in another PD study [@b16] and expert opinion, a total sample of 61 evaluable patients in each arm was calculated to provide 80% power to detect a minimum difference of 3.3 points in BDI-IA total score at the 5% two-sided significance level, assuming a standard deviation of 6.4.

Results
=======

Patient disposition
-------------------

One hundred and twenty-three patients were enrolled and randomized in the study (Fig.[1](#fig01){ref-type="fig"}; Table[1](#tbl1){ref-type="table"}). Seven patients were randomized but did not have a valid post-baseline assessment of the primary efficacy variable. The safety population included 123 (100.0%) patients and the FAS included 116 (94.3%) patients. A total of 106 (86.2%) patients completed the study.

###### 

Demographics and baseline disease characteristics (safety population)

  Parameter (safety population)             Rasagiline (*N* = 58)   Placebo (*N* = 65)
  ----------------------------------------- ----------------------- --------------------
  Male gender, *n* (%)                      27 (46.6%)              38 (58.5%)
  Age (years), mean ± SD                    66.0 ± 8.74             66.1 ± 8.35
  Number of years in education, mean ± SD   9.1 ± 4.33              9.6 ± 4.49
  Duration of PD (years), mean ± SD         3.7 ± 3.17              4.8 ± 3.78
  Hoehn and Yahr staging, *n* (%)                                   
   Stage 1                                  9 (15.5%)               9 (13.8%)
   Stage 1.5                                12 (20.7%)              11 (16.9%)
   Stage 2                                  29 (50.0%)              34 (52.3%)
   Stage 2.5                                5 (8.6%)                6 (9.2%)
   Stage 3                                  3 (5.2%)                5 (7.7%)
  BDI-IA score, mean ± SD                   20.2 ± 5.34             20.1 ± 6.56
  MMSE, mean ± SD                           28.7 ± 1.96             28.8 ± 1.21
  Current PD medications, *n* (%)                                   
   Levodopa                                 36 (62.1%)              45 (69.2%)
   Levodopa/carbidopa/entacapone            5 (8.6%)                14 (21.5%)
   Me-levodopa                              7 (12.1%)               4 (6.2%)
   Ropinirole                               9 (15.5%)               8 (12.3%)
   Pramipexole                              19 (32.8%)              31 (47.7%)
   Rotigotine                               5 (8.6%)                3 (4.6%)
   Entacapone                               2 (3.4%)                --

PD, Parkinson's disease; BDI-IA, Beck Depression Inventory; MMSE, Mini-Mental State Examination.
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Demographics, baseline characteristics and concomitant medications
------------------------------------------------------------------

Patient demographics and baseline PD characteristics were well matched, with no significant differences between groups (*P* \> 0.05 for all) (Table[1](#tbl1){ref-type="table"}).

Efficacy
--------

After 4 weeks of treatment, there was a significant difference between the BDI-IA total score reduction from baseline between groups (marginal means difference ± SE: rasagiline −5.46 ± 0.73 vs. placebo −3.22 ± 0.67; *P* = 0.026). However, after 12 weeks of treatment (primary efficacy end-point) there was no significant difference between groups (marginal means difference ± SE: rasagiline −5.40 ± 0.79 vs. placebo −4.43 ± 0.73; *P* = 0.368). Figure[2](#fig02){ref-type="fig"} shows that the response to rasagiline remained stable from week 4 but there was an improvement with placebo.
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After 12 weeks of treatment there were no significant differences between groups on any of the individual cognitive tests contained within the battery (Table[2](#tbl2){ref-type="table"}).

###### 

Cognitive battery scores

  Variable (FAS population)                    Baseline score (mean ± SD)   Change from baseline at week 12 (mean ± SD)
  -------------------------------------------- ---------------------------- ---------------------------------------------
  Language                                                                  
   ENPA                                                                     
   Placebo                                     17.90 ± 3.23 (*n* = 63)      −0.44 ± 2.85 (*n* = 61)
   Rasagiline                                  17.03 ± 4.37 (*n* = 53)      −0.68 ± 2.85 (*n* = 52)
  Memory                                                                    
   RAVLT immediate recall                                                   
    Placebo                                    34.49 ± 37.59 (*n* = 63)     −1.58 ± 38.51 (*n* = 60)
    Rasagiline                                 36.85 ± 11.75 (*n* = 53)     2.27 ± 10.79 (*n* = 52)
   RAVLT delayed recall                                                     
    Placebo                                    6.57 ± 3.34 (*n* = 63)       1.21 ± 2.53 (*n* = 61)
    Rasagiline                                 7.13 ± 3.65 (*n* = 53)       0.92 ± 2.27 (*n* = 52)
  Attention                                                                 
   Word reading Stroop test                                                 
    Placebo                                    48.10 ± 17.85 (*n* = 62)     −0.92 ± 13.64 (*n* = 60)
    Rasagiline                                 46.08 ± 18.48 (*n* = 53)     −1.29 ± 9.57 (*n* = 52)
   Color naming Stroop test                                                 
    Placebo                                    31.37 ± 13.89 (*n* = 62)     0.32 ± 9.71 (*n* = 60)
    Rasagiline                                 31.87 ± 9.94 (*n* = 53)      −1.65 ± 5.85 (*n* = 52)
   Trails A                                                                 
    Placebo                                    68.97 ± 53.32 (*n* = 63)     −7.78 ± 46.81 (*n* = 59)
    Rasagiline                                 58.31 ± 30.17 (*n* = 52)     −1.10 ± 17.40 (*n* = 51)
  Frontal functions                                                         
   Trails B                                                                 
    Placebo                                    160.09 ± 97.02 (*n* = 54)    4.28 ± 70.04 (*n* = 50)
    Rasagiline                                 157.87 ± 86.75 (*n* = 47)    −4.22 ± 53.03 (*n* = 46)
   Trails B−A                                                               
    Placebo                                    99.56 ± 77.03 (*n* = 54)     6.24 ± 69.34 (*n* = 50)
    Rasagiline                                 100.79 ± 82.32 (*n* = 47)    −3.50 ± 48.63 (*n* = 46)
   Stroop test non-congruent correct answers                                
    Placebo                                    17.41 ± 13.21 (*n* = 61)     0.58 ± 13.18 (*n* = 59)
    Rasagiline                                 17.10 ± 7.47 (*n* = 52)      0.39 ± 4.30 (*n* = 51)
   Clock Drawing Test                                                       
    Placebo                                    8.97 ± 10.19 (*n* = 63)      −0.63 ± 12.88 (*n* = 59)
    Rasagiline                                 6.88 ± 3.44 (*n* = 53)       0.33 ± 3.40 (*n* = 52)
   CPT for letter                                                           
    Placebo                                    27.00 ± 11.45 (*n* = 63)     0.36 ± 7.18 (*n* = 61)
    Rasagiline                                 29.13 ± 14.44 (*n* = 53)     −2.12 ± 9.35 (*n* = 52)
   CPT for categories                                                       
    Placebo                                    22.40 ± 15.10 (*n* = 63)     0.62 ± 6.85 (*n* = 61)
    Rasagiline                                 22.28 ± 14.46 (*n* = 52)     1.71 ± 10.86 (*n* = 50)
  Visuospatial function                                                     
   BJLOT                                                                    
    Placebo                                    19.38 ± 7.50 (*n* = 63)      0.84 ± 7.18 (*n* = 61)
    Rasagiline                                 21.85 ± 8.40 (*n* = 52)      0.98 ± 3.73 (*n* = 51)
   ROCF copy                                                                
    Placebo                                    26.83 ± 12.23 (*n* = 63)     0.07 ± 11.21 (*n* = 56)
    Rasagiline                                 28.50 ± 6.84 (*n* = 52)      −1.13 ± 6.88 (*n* = 51)

FAS, full-analysis set; ENPA, Aphasia Neuropsychological Examination (Esame Neuropsicologico per l'Afasia in Italian); RAVLT, Rey Auditory Verbal Learning Test; Trails, Trail Making Test, parts A and B; CPT, Cognitive Performance Test for letters and categories; BJLOT, Benton Judgment of Line Orientation Test; ROCF, Rey--Osterrieth Complex Figure test.

Treatment with rasagiline significantly improved UPDRS Part II scores versus placebo at week 12 (marginal means difference ± SE: rasagiline −1.37 ± 0.35 vs. placebo 0.06 ± 0.32; *P* = 0.003). There was no significant effect of treatment on UPDRS Part III subscores (rasagiline −0.88 ± 0.56 vs. placebo 0.42 ± 0.51; *P* = 0.090). There was a significant difference between groups on UPDRS Part I subscores (rasagiline −0.96 ± 0.16 vs. placebo −0.49 ± 0.15; *P* = 0.030) (Table[3](#tbl3){ref-type="table"}). *Post hoc* analysis of individual UPDRS Part I items also found a significant between-group difference for depression (rasagiline −0.59 ± 0.09 vs. placebo −0.28 ± 0.08; *P* = 0.041). There were no significant differences in other individual UPDRS Part I items.

###### 

Change from baseline in UPDRS subdomains

  Variable (FAS population)   Baseline score (mean ± SD)   Change from baseline at week 12 (marginal mean ± SE)
  --------------------------- ---------------------------- ----------------------------------------------------------
  Subdomains of UPDRS                                      
   Mentation                                               
    Placebo                   0.37 ± 0.52 (*N* = 63)       −0.04 ± 0.05 (*N* = 60)
    Rasagiline                0.38 ± 0.53 (*N* = 52)       −0.09 ± 0.06 (*N* = 52)
   Thought disorder                                        
    Placebo                   0.27 ± 0.48 (*N* = 63)       −0.04 ± 0.04 (*N* = 60)
    Rasagiline                0.17 ± 0.43 (*N* = 52)       −0.07 ± 0.05 (*N* = 52)
   Depression                                              
    Placebo                   1.68 ± 0.74 (*N* = 63)       −0.28 ± 0.08 (*N* = 60)
    Rasagiline                1.56 ± 0.70 (*N* = 52)       −0.59 ± 0.09[\*](#tf3-2){ref-type="table-fn"} (*N* = 52)
   Motivation/initiative                                   
    Placebo                   1.13 ± 0.87 (*N* = 63)       −0.07 ± 0.08 (*N* = 60)
    Rasagiline                1.06 ± 0.94 (*N* = 52)       −0.33 ± 0.09 (*N* = 52)

UPDRS, Unified Parkinson's Disease Rating Scale; FAS, full-analysis set.

Significant difference.

There was no significant effect of treatment on PDQ-39 total scores (rasagiline −6.28 ± 2.24 vs. placebo −0.73 ± 2.06; *P* = 0.074). However, a *post hoc* analysis of PDQ-39 domains found significant differences favouring rasagiline in PDQ-mobility scores (*P* = 0.007) and PDQ-cognition scores (*P* = 0.026) (Table[4](#tbl4){ref-type="table"}). No significant between-group differences were noted for apathy as assessed by the AS.

###### 

Change from baseline in PDQ-39 domains

  Variable (FAS population)     Baseline score (mean ± SD)   Change from baseline at week 12 (marginal mean ± SE)
  ----------------------------- ---------------------------- ----------------------------------------------------------
  Domains of PDQ-39                                          
   Mobility                                                  
    Placebo                     35.01 ± 21.44 (*N* = 62)     2.83 ± 2.33 (*N* = 59)
    Rasagiline                  31.37 ± 25.26 (*N* = 53)     −6.28 ± 2.62[\*](#tf4-2){ref-type="table-fn"} (*N* = 52)
   Activities of daily living                                
    Placebo                     30.22 ± 22.65 (*N* = 63)     1.51 ± 2.33 (*N* = 60)
    Rasagiline                  24.47 ± 20.13 (*N* = 53)     −3.64 ± 2.62 (*N* = 52)
   Emotional well-being                                      
    Placebo                     43.16 ± 18.75 (*N* = 63)     −2.33 ± 2.23 (*N* = 60)
    Rasagiline                  38.19 ± 19.88 (*N* = 53)     −5.66 ± 2.54 (*N* = 52)
   Stigma                                                    
    Placebo                     32.18 ± 22.59 (*N* = 61)     −0.27 ± 2.54 (*N* = 58)
    Rasagiline                  17.46 ± 20.19 (*N* = 53)     −4.58 ± 2.90 (*N* = 51)
   Social support                                            
    Placebo                     13.45 ± 18.15 (*N* = 63)     1.03 ± 2.43 (*N* = 59)
    Rasagiline                  8.02 ± 12.11 (*N* = 53)      −1.44 ± 2.76 (*N* = 51)
   Cognition                                                 
    Placebo                     28.42 ± 17.91 (*N* = 61)     2.41 ± 2.03 (*N* = 59)
    Rasagiline                  25.47 ± 19.06 (*N* = 53)     −4.00 ± 2.28[\*](#tf4-2){ref-type="table-fn"} (*N* = 52)
   Communication                                             
    Placebo                     23.55 ± 24.98 (*N* = 62)     −1.53 ± 2.22 (*N* = 59)
    Rasagiline                  16.34 ± 20.07 (*N* = 53)     −6.60 ± 2.52 (*N* = 51)
   Bodily discomfort                                         
    Placebo                     36.90 ± 24.26 (*N* = 63)     2.72 ± 2.65 (*N* = 60)
    Rasagiline                  33.80 ± 23.42 (*N* = 53)     2.01 ± 2.97 (*N* = 52)
   Total                                                     
    Placebo                     51.65 ± 26.88 (*N* = 62)     −1.03 ± 2.33 (*N* = 60)
    Rasagiline                  41.46 ± 23.03 (*N* = 52)     −6.24 ± 2.69 (*N* = 51)

PDQ-39, Parkinson's disease quality of life questionnaire; FAS, full-analysis set.

Significant difference.

Safety
------

A total of 15 vs. 17 patients (rasagiline versus placebo group, respectively) reported at least one TEAE; most TEAEs were mild or moderate. No TEAE was reported more than two times in either group. Two patients in the rasagiline group (radius fracture; melanocytic nevus) and one in the placebo group (polyneuropathy in malignant disease and respiratory disorder) reported a serious TEAE. Four patients in the rasagiline group withdrew due to an TEAE (aggravated dyskinesia, vertigo, left trunk flexion due to PD, nausea) versus none in the placebo group.

Discussion
==========

To the best of our knowledge this is the first prospective study exploring the efficacy of rasagiline versus placebo on depressive symptoms in PD. The primary end-point, change from baseline to week 12, was not achieved although a significant difference favouring rasagiline was observed at 4 weeks. Likewise, the pre-planned analyses did not find any significant differences in cognitive function.

One potential reason for the lack of efficacy on depressive symptoms may be the BDI-IA inclusion criteria, which selected patients with at least a moderate severity of depressive symptoms (baseline BDI-IA scores were 20 in both groups). It may be that the effects of simply enhancing the dopaminergic system by inhibiting dopamine metabolism are not enough to treat moderate to severe depressive symptoms. The only antiparkinsonian therapy that has been shown in a randomized controlled trial to improve depressive symptoms in PD is pramipexole (patients in the pramipexole trial had milder baseline BDI scores of 18.7--19.5) [@b16], which has been shown to bind with high affinity to dopamine D3 receptors in the prefrontal cortex, amygdala, and medial and lateral thalamus (all known to have some relation to depression) [@b17]. In addition, the improvement in depressive symptomology in the placebo group between weeks 4 and 12 probably reflects the positive influence of being in a study for depression (e.g. increased contact with healthcare professionals and expectations of improvement) [@b18].

By contrast, *post hoc* analysis of the UPDRS Part I did show a significant effect on the depression item. This probably reflects the less comprehensive assessment of depressive symptoms by just one item versus a 21-item questionnaire specifically designed to assess depression. Interestingly, the ADAGIO delayed-start study, which was conducted in patients with early PD and included an assessment of non-motor experiences of daily living (nM-EDL) in the placebo-controlled phase, also found that treatment with rasagiline 1 mg/day significantly improved the depression item versus placebo. Although baseline depression was not specifically assessed in ADAGIO, baseline nM-EDL scores were low suggesting that patients had less severe symptoms [@b13],[@b14]. More recently, an analysis of the 191 ADAGIO patients who were concomitantly treated with antidepressants found that depression and cognition item scores improved significantly in the rasagiline group compared with the placebo group [@b19]. Importantly, the effect on depressive symptoms remained significant after controlling for motor change, thereby confirming some sort of role for the dopamine system in depression in PD.

Taken together, the secondary efficacy results do not show a clear effect of rasagiline on cognitive function. Thus far, only one small study has been published exploring the efficacy of rasagiline on cognitive function [@b15]. This study conducted in 55 PD patients found that rasagiline provides significant improvements in attention (as measured by digit span) and executive functions (as measured by verbal fluency). However, the study specifically excluded patients with a geriatric depression scale score \>13, thereby excluding patients with all but the mildest depressive symptoms. The discordance between the results of the earlier study and ours might reflect different methodologies used to assess cognitive functions and different sizes in PD samples.

As with other studies, treatment with rasagiline improved both UPDRS mental and ADL scores [@b12]. The effects on motor function did not reach statistical significance but all patients already had a stable motor component and there was no requirement for additional therapy. Although improvements in ADL are mostly driven by motor function, they are derived from the patients self-report over the past week and also include non-motor aspects of the disease. From the patients' perspective, overall quality of life (as self-reported using the PDQ-39) was not found to significantly improve with rasagiline, but patients were able to identify improvements in mobility and in cognition. The improvement of the PDQ-mobility item is expected because it reflects the trend towards improvement of UPDRS motor scores. However, the effects on cognition are not consistent with the results of objective neuropsychological results. As already noted, the PDQ-39 is a self-administered test, and thus the results reflect patients' own impressions of their overall cognitive status versus the very specific cognitive tests employed in the test battery.

The strengths of this study include its randomized, placebo-controlled design, prospective nature and its reasonable size. However, our study has several important limitations. Patients with milder depressive symptoms, those already treated with antidepressants and those with motor fluctuations were excluded from the study and it was only of a short (12 weeks) duration. Recruitment was slow, and eventually there were fewer than the estimated 61 patients in the FAS for the rasagiline group -- implying that the study could be underpowered for testing the primary and secondary outcomes. In addition, the large number of tests (including 13 cognitive tests) employed meant that there were a high number of statistical tests with no correction for multiplicity and the analyses of UPDRS Part I items and PDQ domains were conducted *post hoc*. Finally, it should be noted that, at the time this study was conducted, the concept of mild cognitive impairment (MCI) in PD was not universally accepted, and as such no data were available on the MCI status of patients in this study. Future studies would need to collect such MCI data.

In summary, rasagiline was not found to have significant effects versus placebo in PD patients with moderately severe depressive symptoms. However, *post hoc* analyses and patient self-reported measures do appear to signal some improvements in both depression and cognition. Taken together with the results of other recently reported analyses [@b13],[@b19], this study supports the suggestion that studies in PD patients with milder depressive symptoms are warranted.
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